Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study

In PD-L1 TPS ≥ 50% NSCLC patients treated with pembrolizumab, our results suggest an improved PFS in patients predicted to be KEAP1/NFE2L2 mutated.

Authors

R. Descourt (ORCID: https://orcid.org/0000-0003-2385-9507)
Coline Le Meur
Vincent Bourbonne (ORCID: https://orcid.org/0000-0002-2631-0029)
Matthieu Chasseray
Ronan Abgral (ORCID: https://orcid.org/0000-0002-5585-2564)
David Bourhis (ORCID: https://orcid.org/0000-0001-8224-2027)
Karim Amrane (ORCID: https://orcid.org/0000-0001-5166-6548)
Olivier Pradier

Institutions

Inserm (FR)
Université de Bretagne Occidentale (FR)
Centre Hospitalier Régional Universitaire de Brest (FR)
Clinique Pasteur (FR)
Centre Hospitalier des Pays de Morlaix (FR)
Laboratoire de Traitement de l'Information Médicale (FR)

Publication Details

Journal: Cancer Imaging
Published: 2025-11-22
DOI: https://doi.org/10.1186/s40644-025-00957-y
Primary Topic: Radiomics and Machine Learning in Medical Imaging
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study

R. Descourt, Coline Le Meur, Vincent Bourbonne, Matthieu Chasseray et al.

Nov 22, 2025

Cancer Imaging

Radiomics and Machine Learning in Medical Imaging

article

Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study

R. Descourt, Coline Le Meur, Vincent Bourbonne, Matthieu Chasseray, Ronan Abgral, David Bourhis, Karim Amrane, Olivier Pradier

November 22, 2025article en

Abstract

In PD-L1 TPS ≥ 50% NSCLC patients treated with pembrolizumab, our results suggest an improved PFS in patients predicted to be KEAP1/NFE2L2 mutated.

Cancer ImagingVol. 25(1)

Inserm (FR), Université de Bretagne Occidentale (FR), Centre Hospitalier Régional Universitaire de Brest (FR), Clinique Pasteur (FR), Centre Hospitalier des Pays de Morlaix (FR), Laboratoire de Traitement de l'Information Médicale (FR)

Openalex Percentile: Top 49%

Radiomics and Machine Learning in Medical Imaging

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study — R. Descourt, Coline Le Meur, et al. · Cancer Imaging (2025) | TGRS Research Map | TGRS